Incannex Healthcare Ltd ADR (IXHL) - Total Assets
Based on the latest financial reports, Incannex Healthcare Ltd ADR (IXHL) holds total assets worth $75.01 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Incannex Healthcare Ltd ADR - Total Assets Trend (2006–2025)
This chart illustrates how Incannex Healthcare Ltd ADR's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Incannex Healthcare Ltd ADR - Asset Composition Analysis
Current Asset Composition (June 2025)
Incannex Healthcare Ltd ADR's total assets of $75.01 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 73.6% |
| Accounts Receivable | $4.63 Million | 22.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Incannex Healthcare Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Incannex Healthcare Ltd ADR's current assets represent 97.6% of total assets in 2025, an increase from 5.5% in 2006.
- Cash Position: Cash and equivalents constituted 73.6% of total assets in 2025, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 22.6% of total assets.
Incannex Healthcare Ltd ADR Competitors by Total Assets
Key competitors of Incannex Healthcare Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Painreform Ltd
NASDAQ:PRFX
|
USA | $11.16 Million |
|
Zhejiang Nhu Co Ltd
SHE:002001
|
China | CN¥45.09 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Prestige Brand Holdings Inc
NYSE:PBH
|
USA | $3.49 Billion |
Incannex Healthcare Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 48.27 | 1.80 | 12.36 |
| Quick Ratio | 48.27 | 1.80 | 12.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $73.13 Million | $4.66 Million | $2.14 Million |
Incannex Healthcare Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Incannex Healthcare Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.55 |
| Latest Market Cap to Assets Ratio | 1.86 |
| Asset Growth Rate (YoY) | 19.9% |
| Total Assets | $20.45 Million |
| Market Capitalization | $38.01 Million USD |
Valuation Analysis
Above Book Valuation: The market values Incannex Healthcare Ltd ADR's assets above their book value (1.86x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Incannex Healthcare Ltd ADR's assets grew by 19.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Incannex Healthcare Ltd ADR (2006–2025)
The table below shows the annual total assets of Incannex Healthcare Ltd ADR from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $20.45 Million | +19.94% |
| 2024-06-30 | $17.05 Million | -28.32% |
| 2023-06-30 | $23.78 Million | -9.06% |
| 2022-06-30 | $26.15 Million | +273.13% |
| 2021-06-30 | $7.01 Million | +140.80% |
| 2020-06-30 | $2.91 Million | +700.52% |
| 2019-06-30 | $363.60K | -30.60% |
| 2018-06-30 | $523.91K | -31.85% |
| 2017-06-30 | $768.72K | +198.67% |
| 2016-06-30 | $257.38K | -94.63% |
| 2015-06-30 | $4.79 Million | -34.50% |
| 2014-06-30 | $7.31 Million | -58.78% |
| 2013-06-30 | $17.74 Million | -27.21% |
| 2012-06-30 | $24.38 Million | +13.38% |
| 2011-06-30 | $21.50 Million | +58.73% |
| 2010-06-30 | $13.55 Million | +14.43% |
| 2009-06-30 | $11.84 Million | +16.64% |
| 2008-06-30 | $10.15 Million | +75.52% |
| 2007-06-30 | $5.78 Million | +364.92% |
| 2006-06-30 | $1.24 Million | -- |
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more